Abstract:
Objective: To determine whether 17 alpha-hydroxyprogesterone caproate (17OHPC) prolongs gestation beyond 37 weeks of gestation (primary outcome) and reduces neonatal morbidity (secondary outcome) in twin pregnancy. Design: Randomised controlled double-blind clinical trial. Setting: Tertiary-care university medical centre. Population: Unselected women with twin pregnancies. Methods: Participants received weekly injections of 250 mg 17OHPC (n = 194) or placebo (n = 94), from 16-20 to 36 weeks of gestation. Randomisation was performed using the permuted-block randomisation method. Data were analysed on an intention-to-treat basis. Main outcome measure: Preterm birth (PTB) rate before 37 weeks of gestation. Results: There were no significant differences in the average gestational age at delivery, or in the rates of PTB before 37, 32, and 28 weeks of gestation, between the two groups. The proportion of very-low-birthweight neonates (1500 g) was significantly lower in the 17OHPC group (7.6percent) compared with placebo (14.3percent) (relative risk, RR 0.5; 95percent confidence interval, 95percent CI 0.3-0.9; P = 0.01). Progestogen-treated neonates had a significantly lower composite neonatal morbidity (19.1percent) compared with placebo (30.9percent) (odds ratio, OR 0.53; 95percent CI 0.31-0.90; P = 0.02), with significantly lower odds for respiratory distress syndrome (14.4 versus 23.4percent; OR 0.55; 95percent CI 0.31-0.98; P = 0.04), retinopathy of prematurity (1.1 versus 4.6percent; OR 0.21; 95percent CI 0.05-0.96; P = 0.04), and culture-confirmed sepsis (3.4 versus 12.8percent; OR 0.24; 95percent CI 0.10-0.57; P = 0.00). Conclusions: Intramuscular 17OHPC therapy did not reduce PTB before 37 weeks of gestation in unselected twin pregnancies. Nonetheless, 17OHPC significantly reduced neonatal morbidity parameters and increased birthweight. © 2014 Royal College of Obstetricians and Gynaecologists.